CABALETTA BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.86 USD | +3.79% |
|
+22.71% | -43.35% |
| Mar. 22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
| Mar. 21 | Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 5.56M | Capitalization | 598M |
|---|---|---|---|---|---|
| Net income 2024 * | -92M | Net income 2025 * | -109M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 258M | Net cash position 2025 * | 181M | EV / Sales 2025 * | 75.1 x |
| P/E ratio 2024 * |
-6.55
x | P/E ratio 2025 * |
-5.87
x | Employees | 102 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.49% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cabaletta Bio, Inc.
More recommendations
More press releases
| 1 day | +3.79% | ||
| 1 week | +22.71% | ||
| Current month | +20.81% | ||
| 1 month | -24.26% | ||
| 3 months | -43.22% | ||
| 6 months | -16.06% | ||
| Current year | -43.35% |
1 week
10.56
13.30
1 month
9.7519.04
Current year
9.7526.35
1 year
9.0226.35
3 years
0.5926.35
5 years
0.5926.35
10 years
0.5926.35
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 17-03-31 | |
Anup Marda
DFI | Director of Finance/CFO | 46 | 18-12-31 |
| Compliance Officer | - | 19-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 19-02-18 | |
| Chief Executive Officer | 62 | 17-03-31 | |
Mark Simon
BRD | Director/Board Member | 62 | 18-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +3.34% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 12.86 | +3.79% | 1,031,674 |
| 24-05-03 | 12.39 | -1.67% | 817,484 |
| 24-05-02 | 12.6 | +1.53% | 1,808,592 |
| 24-05-01 | 12.41 | +16.58% | 2,809,408 |
| 24-04-30 | 10.64 | +1.57% | 1,934,233 |
Delayed Quote Nasdaq, May 06, 2024 at 04:30 pm EDT
More quotes
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
12.39
USD
Average target price
34.5
USD
Spread / Average Target
+178.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -43.35% | 598M | |
| +9.15% | 105B | |
| -1.08% | 104B | |
| +5.79% | 22.94B | |
| -11.55% | 22.34B | |
| -7.01% | 19.25B | |
| -37.08% | 17.08B | |
| -9.91% | 16.96B | |
| +7.55% | 14.16B | |
| +40.04% | 12.63B |
- Stock Market
- Equities
- CABA Stock